Vega Therapeutics is developing VGA039, a monoclonal antibody therapy that targets Protein S to enhance thrombin generation in patients with von Willebrand disease (VWD). This therapy aims to provide a subcutaneous treatment option that reduces the burden of frequent IV infusions and improves the quality of life for individuals suffering from this often-overlooked bleeding disorder.
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Von Willebrand disease (VWD), the most common bleeding disorder, is often overlooked and underdiagnosed, leading to delayed treatment and a high burden on patients. Current VWD treatments have limitations, including few prophylaxis options and the need for frequent intravenous infusions, impacting patients' quality of life.
Solution
Vega Therapeutics is developing VGA039, a first-in-class monoclonal antibody therapy that targets Protein S to restore balance to the blood clotting process in VWD patients. VGA039 is designed for subcutaneous administration, offering a more convenient treatment option compared to intravenous infusions. By targeting Protein S, VGA039 aims to enhance thrombin generation and improve blood clotting, potentially preventing and managing bleeding episodes. The therapy is currently being studied in the VIVID clinical trial to evaluate its safety and efficacy in transforming the treatment experience for individuals living with VWD.
Target Audience
The primary target audience includes individuals diagnosed with von Willebrand disease (VWD) who require more convenient and effective treatment options, as well as hematologists and healthcare providers specializing in bleeding disorders.
Features
- Subcutaneous administration for convenient self-administration.
- Monoclonal antibody targeting Protein S to restore balance in blood clotting.
- Designed to enhance thrombin generation and improve blood clotting.
- First-in-class therapy with a novel mechanism of action.
- Currently in clinical trials to assess safety and efficacy.